ABL1 and leukemia: Imatinib (Gleevec) which targets the ATP-binding site of different tyrosine kinases including BCR-ABL [9], [10], selectively induces growth arrest and apoptosis of BCR-ABL positive leukemia cells with minimal effect on normal hematopoietic progenitors [11], [12], [13].